Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.
Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin. Corticosteroids are the mainstay of therapy of dermatomyositis, and severe morbidity and mortality occurs in part through the known long-term side effects of chronic steroid use. In addition, dermatomyositis is commonly associated with underlying malignancy, and high-dose steroids may adversely impair treatment of these malignancies. We describe the first use of rapamycin in a young patient with dermatomyositis.
Nadiminti
Uma
U
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Arbiser
Jack L
JL
D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy; D003882:Dermatomyositis / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011241:Prednisone; D020123:Sirolimus